Cancer Research Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT04625270
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
This study is not currently enrolling.Associated Conditions: Ovarian, Fallopian, or Primary Peritoneum CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main aims of this clinical study are to: (a) Find out if the best course of study treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with...
-
Prospective Registry for Colorectal Cancer: International Watch and Wait Database
This study is not currently enrolling.Associated Conditions: Colorectal CancerResearch Area: Clinical Cancer ResearchThis research is being done as part of a larger international database for 'Watch and Wait' rectal cancer patients. Currently, the 'Watch and Wait' treatment shows promising results worldwide, however...
-
NCT04284774
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThis is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second...
-
NCT04195555
APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations.
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe main goal is to find out what effect, good and/or bad effects AG-120 (ivosidenib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by AG-120 (ivosidenib)...
-
NCT03919071
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
This study is not currently enrolling.Associated Conditions: Brain CancerResearch Area: Clinical Cancer ResearchThe study doctors want to see if using dabrafenib and trametinib after radiation treatment will be better than treatments used in the past in helping to get rid of or shrink HGGs. Dabrafenib works by...
-
NCT03220035
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations
This study is not currently enrolling.Associated Conditions: Cancer, All Tumor TypesResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaYou are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the...
-
NCT03324841
Caris Molecular Intelligence and Caris Centers of Excellence for Precision Medicine Network Outcomes Associated Repository
This study is not currently enrolling.Research Area: Clinical Cancer ResearchThe purpose of the research repository is to collect information, which will be used for research studies to evaluate how clinical outcomes relate to Caris Molecular INtelligence Services.
-
NCT03213704
NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
This study is not currently enrolling.Associated Conditions: Cancer, Companion StudyResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.
-
NCT03233711
A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer
This study is not currently enrolling.Associated Conditions: Anal CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO), after standard chemotherapy {(mitomycin-C and 5-fluorouracil 5(-RU) or capecitabine) or 5-FU and...
-
NCT03856099
A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy
This study is not currently enrolling.Associated Conditions: Brain CancerResearch Area: Clinical Cancer ResearchThe aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to...
-
NCT03126916
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
This study is not currently enrolling.Associated Conditions: Brain CancerResearch Area: Clinical Cancer ResearchThe overall goals of this study are to: Compare the effects, good and/or bad, of the experimental drug 131I-MIBG added to current COG recommended therapy to the effects of current COG recommended...
-
NCT00736749
Umbrella Long-Term Follow-Up Protocol
This study is not currently enrolling.Associated Conditions: Companion StudyResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to keep in contact with participants of COG clinical trials, so that up-to-date information will be available about these participants as they get older. This...